Catriona Yale Sells 10,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 10,000 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.76, for a total transaction of $447,600.00. Following the sale, the insider now directly owns 95,034 shares in the company, valued at approximately $4,253,721.84. This represents a 9.52 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Wednesday, March 12th, Catriona Yale sold 614 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.88, for a total transaction of $27,556.32.
• On Tuesday, February 18th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $49.87, for a total value of $498,700.00.

Akero Therapeutics Trading Up 1.3 %

Shares of AKRO stock traded up $0.56 during mid-day trading on Friday, hitting $45.22. 2,928,554 shares of the company's stock were exchanged, compared to its average volume of 810,903. The stock has a market cap of $3.60 billion, a price-to-earnings ratio of -12.06 and a beta of -0.19. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $58.40. The stock has a 50-day simple moving average of $43.93 and a two-hundred day simple moving average of $34.40.

Remove Ads

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). Equities analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on AKRO. HC Wainwright upped their target price on Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a report on Monday, March 3rd. UBS Group raised their target price on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a report on Friday, January 31st. Canaccord Genuity Group upped their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Bank of America raised shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $35.00 to $63.00 in a research note on Thursday, January 30th. Finally, Citigroup upped their target price on Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $76.29.

Institutional Investors Weigh In On Akero Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Victory Capital Management Inc. acquired a new position in shares of Akero Therapeutics in the 3rd quarter valued at $211,000. LMR Partners LLP boosted its holdings in Akero Therapeutics by 17.0% in the third quarter. LMR Partners LLP now owns 20,597 shares of the company's stock valued at $591,000 after acquiring an additional 2,997 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Akero Therapeutics during the third quarter valued at about $491,000. Algert Global LLC increased its stake in Akero Therapeutics by 8.3% during the third quarter. Algert Global LLC now owns 68,052 shares of the company's stock worth $1,952,000 after acquiring an additional 5,191 shares during the last quarter. Finally, Summit Financial Wealth Advisors LLC purchased a new position in shares of Akero Therapeutics in the 3rd quarter worth about $205,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.